HOME > TOP STORIES

TOP STORIES

REGULATORY Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars

March 16, 2015
REGULATORY PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018

March 13, 2015
BUSINESS Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers

March 13, 2015
ORGANIZATION JSGM President Calls for Generic Share Target of 80% by FY2020

March 12, 2015
BUSINESS Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?

March 12, 2015
BUSINESS AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse

March 11, 2015
BUSINESS Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?

March 11, 2015
REGULATORY MHLW to Target 75% Generic Share for Welfare Recipients

March 10, 2015
ACADEMIA Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data

March 9, 2015
ACADEMIA Interview on SGLT-2 Inhibitor Use (1): Prof. Ueki Says Flat Sales Reflect Cautious Prescribing by Physicians

March 6, 2015
BUSINESS Pfizer Japan Sales Down 5% as Generic Erosion Weighs

March 5, 2015
BUSINESS Weber to Become CEO of Takeda in April

March 4, 2015
REGULATORY Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable

March 3, 2015
BUSINESS Eli Lilly Aims to Lead Japan Diabetes Market by 2020

March 2, 2015
REGULATORY Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting

February 27, 2015
ACADEMIA Govt-Backed Research Center Looks to License Malaria Vaccine to Mega Pharma

February 27, 2015
REGULATORY MHLW OKs 60 New APIs in 2014, Doubling from Year Ago

February 26, 2015
BUSINESS Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics

February 25, 2015
BUSINESS Daiichi Sankyo to Shake Up Japan Organization as Olmetec Patent Expiry Nears

February 25, 2015
REGULATORY Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW

February 24, 2015

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…